Potential Novel RNA-Targeting Agents for Effective Lipoprotein(a) Lowering: A Systematic Assessment of the Evidence From Completed and Ongoing Developmental Clinical Trials

• Published in: Journal of cardiovascular pharmacology Vol. 82; no. 1; p. 1
• Main Authors: Milosavljevic, Milos N, Stefanovic, Srdjan M, Pejcic, Ana V
• Format: Journal Article
• Language: English
• Published: United States 01.07.2023
• Subjects: Atherosclerosis - drug therapy; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - prevention & control; Humans; Lipoprotein(a); Oligonucleotides, Antisense - adverse effects; Risk Factors; RNA - therapeutic use

An increase in blood lipoprotein (a) [Lp(a)] levels, mostly genetically determined, has been identified as an independent risk factor of atherosclerotic cardiovascular disease. No drug has yet been approved that markedly lowers Lp(a) and thereby reduces residual cardiovascular risk. The aim of this...